Company: BDRX
Filing Date: 2025-01-17
Form Type: F-1
Source: 0001214659-25-000922
Chunk: 336

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-01-17
Form: F-1
Chunk 336
---
 Selling Shareholder,
any compensation paid by the Selling Shareholder to any such brokers, dealers, underwriters or agents, and any other required information.

We will pay the expenses incident
to the registration under the Securities Act of the offer and sale of our Depositary Shares covered by this prospectus by the Selling
Shareholder. As consideration for its irrevocable commitment to purchase our Depositary Shares under the Purchase Agreement, we have agreed
to issue to the Selling Shareholder 2.5% of the Commitment Amount in Depositary Shares, with 1.75% of such shares paid up front and the
balance pro-rated with each Fixed Purchase, VWAP Purchase or Additional VWAP Purchase, as the case may be. We have also agreed to pay
to the Selling Shareholder $35,000 in cash as reimbursement for the reasonable, out-of-pocket expenses incurred by the Selling Shareholder,
including the legal fees and disbursements of the Selling Shareholder’s legal counsel, in connection with its due diligence investigation
of the Company and in connection with the preparation, negotiation and execution of the Purchase Agreement. See “The Committed Equity Financing” for more information.

| 168 |

We also have agreed to indemnify
the Selling Shareholder and certain other persons against certain liabilities in connection with the offering of our Depositary Shares
offered hereby, including liabilities arising under the Securities Act or, if such indemnity is unavailable, to contribute amounts required
to be paid in respect of such liabilities. The Selling Shareholder has agreed to indemnify us against liabilities under the Securities
Act that may arise from certain written information furnished to us by the Selling Shareholder specifically for use in this prospectus
or, if such indemnity is unavailable, to contribute amounts required to be paid in respect of such liabilities. Insofar as indemnification
for liabilities arising under the Securities Act may be permitted to our directors, officers, and controlling persons, we have been advised
that in the opinion of the SEC this indemnification is against public policy as expressed in the Securities Act and is therefore, unenforceable.

We estimate that the total
expenses, including the Commitment Fee, for the offering will be approximately $1.7 million.

The Selling Shareholder has
represented to us that at no time prior to the date of the Purchase Agreement has the Selling Shareholder or its agents, representatives
or affiliates engaged in or effected, in any manner whatsoever, directly or indirectly, any short sale (as such term is